4,7-Dimethyl-chroman | 60249-22-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 4,7-Dimethyl-chroman
• 英文别名: 4,7-Dimethylchroman；4,7-dimethyl-3,4-dihydro-2H-chromene
• CAS: 60249-22-1
• 化学式: C₁₁H₁₄O
• 分子量: 162.232
• InChiKey: PKGRGODMPUSCKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 alkaline solution 、 三溴化磷 作用下， 生成 4,7-Dimethyl-chroman
  参考文献：
  名称：

  The Hydrogenation of Some Substituted Coumarins¹

  摘要：

  DOI：

  10.1021/ja01868a050

文献信息

• Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
  申请人：Akerman Michelle

  公开号：US20070066647A1

  公开（公告）日：2007-03-22

  The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L 1 , L 2 , M, X, L 3 , and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

  本发明提供了一种化合物，例如用于治疗受试者的代谢紊乱。这些化合物具有一般式I： 其中变量Q、L1、L2、M、X、L3和A的定义在此处提供。本发明还提供了包括这些化合物的组合物，以及使用这些化合物制备药物和治疗代谢紊乱的方法，例如II型糖尿病。
• Preparation and reactivity of α-phenylselenenyl ethers
  作者：David J. Goldsmith、Dennis C. Liotta、Mark Volmer、William Hoekstra、Liladhar Waykole

  DOI：10.1016/s0040-4020(01)96726-2

  日期：1985.1

  α-Phenylsclenenyl cyclic ethers may be prepared by the reactions of either lactols or lactol acetates with benzeneselenol, or from lactones by the “one-pot” process of reduction and Lewis acid catalyzed selenation. The tetrahydropyranyl phenyl selenides also exhibit a significant anomeric effect and its size has been estimated. The selenenyl ethers are converted to enol ethers through an oxidative elimination

  α-苯基亚硒基环状醚可以通过乳醇或乙酸乳醇酯与苯硒酚的反应来制备，或通过“一锅法”还原和路易斯酸催化的硒化反应由内酯制备。四氢吡喃基苯基硒化物也表现出显着的异头作用，并且已经估计了其大小。亚硒基醚通过氧化消除过程被转化为烯醇醚，并且已经探索了它们对酰胺碱和烷基锂的反应性。
• LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
  申请人：INTERMUNE, INC.

  公开号：US20140200215A1

  公开（公告）日：2014-07-17

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

  提供的是化合物、制造这些化合物的方法、包含这些化合物的药物组合物和药品，以及使用这些化合物来治疗、预防或诊断与一个或多个溶血磷脂酸受体相关的疾病、失调或状况的方法。
• [EN] CHROMANE-SUBSTITUED TETRACYCLIC COMPOUNDS AND USES THEREOF FOR TREATMENT OF VIRAL DISEASES<br/>[FR] COMPOSÉS TÉTRACYCLIQUES SUBSTITUÉS PAR CHROMANE ET LEURS UTILISATIONS DANS LE TRAITEMENT DE MALADIES VIRALES
  申请人：MERCK SHARP & DOHME

  公开号：WO2018032467A1

  公开（公告）日：2018-02-22

  Disclosed are novel chromane-substituted tetracyclic compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, A', R2 R3, R4 and R5 are as defined in the description. Also disclosed are compositions comprising a chromane-substituted tetracyclic compound, and methods of using the chromane-substituted tetracyclic compounds for treating or preventing HCV infection in a patient.

  揭示了一种新的Formula (I)的含有色甘醇取代基的四环化合物，以及其药用盐，其中A、A'、R2、R3、R4和R5如描述中所定义。还揭示了包含色甘醇取代基四环化合物的组合物，以及使用这些色甘醇取代基四环化合物来治疗或预防患者HCV感染的方法。
• [EN] HISTONE DEMETHYLASE INHIBITORS<br/>[FR] INHIBITEURS DE L'HISTONE DÉMÉTHYLASE
  申请人：QUANTICEL PHARMACEUTICALS INC

  公开号：WO2016044429A1

  公开（公告）日：2016-03-24

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明通常涉及治疗癌症和肿瘤性疾病的组合物和方法。本文提供了替代的吡啶并[3,4-d]嘧啶-4-酮衍生物化合物和包含该化合物的药物组合物。所述化合物和组合物对组蛋白去甲基化酶的抑制有用。此外，所述化合物和组合物对于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等方面是有用的。